Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
X4 Pharmaceuticals, Inc has 1 disclosed supplier and 3 disclosed customers. Each one is named in an SEC filing, either X4 Pharmaceuticals, Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Prev close 3.62 · gapped below the open, never looked back. High/low 3.62 at 3:45 pm ET, 3.34 at 10:30 am ET.
X4 Pharmaceuticals, Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In July 2014, we entered into a license agreement (the "Genzyme Agreement") with Genzyme Corporation ("Genzyme"), a wholly owned subsidiary of Sanofi, pursuant to which we were granted an exclusive license to certain patent applications and other intellectual property owned or controlled by Genzyme related to the CXCR4 receptor to develop and commercialize products containing licensed compounds, including but not limited to, mavorixafor.”
FILING10-K0001501697-26-000018cik 0001501697
“We also have a license agreement with Abbisko Therapeutics Co. Ltd. ("Abbisko"), which granted Abbisko the exclusive right to perform regulatory activities on, manufacture and distribute mavorixafor in mainland China, Taiwan, Hong Kong and Macau.”
FILING10-K0001501697-26-000018cik 0001501697
“O n January 13, 2025, we announced a License and Supply Agreement (the "Norgine Agreement") with Norgine Pharma UK ("Norgine"), pursuant to which Norgine was granted an exclusive license to distribute, market and sell our drug product for all indications in the European Economic Area, Switzerland, the United Kingdom, Australia, and New Zealand.”
FILING10-K0001501697-26-000018cik 0001501697
“In February 2025, we announced that we had entered into an agreement with Taiba Middle East Fz LLC ("taiba rare") to distribute and commercialize XOLREMDI for the treatment of WHIM syndrome in select Middle East and North African ("MENA") countries.”
FILING10-K0001501697-26-000018cik 0001501697
Watchlist prices, news filtered to it, and its next report on your desk.
XFOR (X4 Pharmaceuticals, Inc) has 1 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.